Roche's com­bo ther­a­py re­duces risk of liv­er can­cer re­turn­ing but rais­es safe­ty ques­tions: #AACR23

OR­LAN­DO — Roche’s Tecen­triq-Avastin com­bi­na­tion, al­ready ap­proved for one in­di­ca­tion, re­duced the risk of can­cer re­cur­rence among pa­tients af­ter they re­ceived surgery for an ear­ly-stage liv­er can­cer.

The Phase III tri­al could change the land­scape of treat­ment for pa­tients in the ear­ly stages of he­pa­to­cel­lu­lar car­ci­no­ma, or HCC, ac­cord­ing to Genen­tech, a unit of Roche. But the re­sults raised po­ten­tial­ly wor­ry­ing safe­ty sig­nals as well, in­clud­ing two pa­tient deaths re­lat­ed to the com­bi­na­tion, though ex­perts said the da­ta were too ear­ly to reach firm con­clu­sions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER